Short answer
Benitec Biopharma Inc. (BNTC) filed its Q4 2025 10-Q quarterly report on Feb 12, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $0 with net income of −$12M.
Q4 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$12M
- −83.2% YoY · −32.0% QoQ
- EPS (diluted)
- −$0.26
- −113.0% YoY · −18.2% QoQ
Source: XBRL data from the Benitec Biopharma Inc. (BNTC) Q4 2025 10-Q on SEC EDGAR. USD.
Benitec Biopharma Inc. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No Risk Factors section provided in the submitted filing text
- No newly added or materially updated risks identifiable from the provided excerpt
- November 2025 securities purchase and underwriting agreements disclosed as exhibits, without associated risk-factor discussion
- No regulatory, operational, competitive, market, or financial risks stated in the provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Benitec Biopharma Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.